BioCryst: Any Potential Future Revenues From BCX4430 Represent Upside, Says Roth Capital
BioCryst Pharmaceuticals (BCRX) today announced the National Institute of Allergy and Infectious Diseases (NIAID) has exercised additional options to conduct Phase I clinical human safety trials of an intramuscular (IM) formulation of BCX4430, as well as efficacy studies in non-human primates to assess effective dose ranges and dose schedules. These options represent an additional $4.1M to BioCryst in order to advance the development of BCX4430 as a treatment for hemorrhagic fever viruses.
In reaction to the news, Roth Capital analyst Ed Arce today reiterated a Buy rating on BCRX with a $20 price target.
Arce noted, “Filovirus disease outbreaks, like the ongoing Ebola epidemic in West Africa, are among the most virulent of any human pathogen, exceeding 90%. With no drugs or vaccines available for these lethal diseases, the U.S. government, through NIAID, has approved additional funding to advance an IND filing for BCX4430 and a Phase I trial, expected 1Q15.” The analyst continued, “BioCryst intends to use future potential government stockpiling orders for both BCX4430 and IV peramivir (influenza), as sources of non-dilutive funding for further development and commercialization of its flagship therapeutic program for the chronic treatment of hereditary angioedema (HAE).”
The analyst concluded, “We do not currently include BCX4430 in our model. As such, any potential future revenues from BCX4430 represent upside to our current estimates.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Ed Arce has a total average return of 29.2% and a 47.4% success rate. Arce has a 143.0% average return when recommending BCRX, and is ranked #243 out of 3228 analysts.
To read more rating news on BCRX click here.